Remix Therapeutics™ to Present at AACR Drug Discovery and Development Conference Portfolio News / By Libby Nunan Remix Therapeutics™ to Present at AACR Drug Discovery and Development Conference Read More »
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer Read More »
Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson’s Disease Portfolio News / By Libby Nunan Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson’s Disease Read More »
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer Portfolio News / By Libby Nunan Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer Read More »
Remix Therapeutics™ and Passage Bio Announce Merger Agreement Portfolio News / By Libby Nunan Remix Therapeutics™ and Passage Bio Announce Merger Agreement Read More »
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors Portfolio News / By Libby Nunan Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors Read More »
Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting Portfolio News / By Libby Nunan Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting Read More »
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms Portfolio News / By Libby Nunan Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms Read More »
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology Portfolio News / By Libby Nunan Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology Read More »
InduPro Therapeutics Appoints Amanda J. Redig, MD, PhD, as Chief Medical Officer Portfolio News / By Libby Nunan InduPro Therapeutics Appoints Amanda J. Redig, MD, PhD, as Chief Medical Officer Read More »
